trial

Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia

NCTId NCT05259306
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Suspended
Enrollment 3 (estimated)
Sponsored by NYU Langone Health
Primary completion 2028-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Suspended
Enrollment
3 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2027-06
Primary completion
2028-06
Eligibility
ALL · 21 Years · 80 Years

Interventions & indications

Drugs
Insightec Exablate Neuro MR-guided focused ultrasound transducer

Sponsors

NYU Langone HealthLead Sponsor

Investigators

1
Alon Mogliner, MD, PhDPrincipal Investigator

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
3
Phase
NA
Primary Completion Date
2028-06
Status
SUSPENDED
relationships
The graph out of here
drug
Insightec Exablate Neuro MR-guided focused ultrasound transducer
drug
lead_sponsor
NYU Langone Health
company
indication
Schizophrenia, Treatment-Resistant
indication
Treatment-resistant Schizophrenia
indication
investigator
Alon Mogliner, MD, PhD
person